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A B S T R A C T
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, and the sixth leading cause of
cancer related death in women overall. Despite improved surgical techniques and advances in chemotherapy,
mortality hardly decreased over the last twenty years. The major problem is that (micro)metastases persevere in
the abdominal cavity, causing incurable tumor recurrence. Therefore, there is an imminent need for new
therapeutic strategies.
Oligonucleotide (ON) based therapies such as RNA interference (RNAi) provide the possibility to speciﬁcally
address disease-related pathways. However, small interfering RNA (siRNA) molecules are unable to enter cells
without a drug delivery system. Therefore, nanocarriers have been developed to aid intracellular delivery of
siRNA. EOC is, in most cases, conﬁned to the abdominal cavity, providing the possibility for peritoneal drug
delivery. As a consequence, EOC should be an ideal candidate for ON therapies as intraperitoneal delivery
reduces sequestration of drug formulations in other organs.
In this review, we will discuss delivery strategies and siRNA targets that have been tested in EOC. Delivery
strategies cover the full range of delivery approaches from polymers to exotic delivery strategies like micro-
bubble based nanoparticles. For siRNA targets, those that aim at re-sensitizing the tumor cells to chemotherapy
can be discriminated from those that reduce growth and metastasis of the tumor cells.
Despite preclinical successes and the advantage that intraperitoneal delivery holds over systemic delivery, no
strategy has made it into the clinic yet. We postulate that conﬁrmatory studies that combine the most promising
delivery approaches with the most promising targets are required to reach a consensus on those formulations
that should be pursued for further (pre-)clinical research.
1. Introduction
Despite its relatively low incidence, epithelial ovarian cancer (EOC)
is the most lethal gynecological malignancy in developed countries, and
the sixth leading cause of cancer-related deaths among women [1]. The
mean age of onset is 63 and 5 year survival is only 46.5% of all stages
and subtypes combined, with the epithelial type as the most common
and most lethal subtype [2]. Survival is particularly low due to the late
onset of symptoms and diagnosis in an advanced stage. Advanced stage
EOC treatment consists of (neo)adjuvant chemotherapy and cytor-
eductive surgery [3]. The aim of the procedure is to remove as much
tumor as possible. However, (micro)metastases almost always perse-
vere within the abdominal cavity, causing tumor recurrence. The
median progression free survival of advanced ovarian cancer is ap-
proximately 18months and a recurring tumor is typically characterized
by increased resistance to chemotherapeutics [3]. Curation is un-
fortunately not possible with current treatment modalities. Therefore,
novel therapeutic options are necessary.
By altering gene expression, it could be possible to decrease tumor
progression and/or increase sensitivity to cytotoxic agents. RNA inter-
ference (RNAi) is a promising method used for this purpose [4]. RNAi
can be induced in several ways and small interfering RNA (siRNA)
molecules are a well-known class of double stranded oligonucleotides of
20–25 base pairs that speciﬁcally induce degradation of mRNA, thereby
creating eﬃcient gene knockdown [4].
The main advantages of siRNA are high speciﬁcity, high eﬃciency, and
low toxicity [5,6]. However, naked siRNA molecules are prone to de-
gradation by RNase. Moreover, siRNA and other oligonucleotides are un-
able to permeate the plasma membrane and therefore do not reach suﬃ-
cient intracellular concentrations to induce eﬀective gene knockdown. Safe
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and eﬃcient transfection methods have therefore been developed. For
clinical applications, these drug delivery systems mostly comprise non-viral
nanoparticles [7].
Conﬁnement in the intraperitoneal cavity, also at advanced stage, is a
key characteristic of EOC. A recent review states that FIGO (International
Federation of Gynaecology and Obstetrics) stage IV disease, which refers to
the stage of disease with extraperitoneal involvement, is present in only
12–33% of the cases at initial diagnose [8]. With an incidence of 33–53%,
pleural eﬀusion is the most common extraperitoneal manifestation of EOC,
followed by liver, subcutaneous/abdominal wall, and extra-abdominal
lymph nodes, whereas brain and bone metastases are uncommon [8].
Therefore, local treatment of the metastastic tumor with IP chemotherapy
after cytoreductive surgery is a feasible method that increases survival in
ovarian cancer patients [9]. Also for nanoparticles, IP application imposes
very diﬀerent boundary conditions on biodistribution.
This review will provide an overview of delivery systems and their
respective targets for siRNA delivery in the context of ovarian cancer.
The Pubmed database was searched according to the search strategy
shown in the supplementary material S1 and key features of the lit-
erature are summarized in comprehensive Tables 1–6 and in graphical
form in Figs. 1 and 3.
The most widely used nanoparticle formulations are polymer and
lipid based (Fig. 1a). Polyethyleneimine (PEI) and chitosan are the most
commonly used polymers. Polymer based nanocarriers are often posi-
tively charged and are therefore able to bind oligonucleotides via
electrostatic interactions with the anionic backbone of nucleic acids.
The positive charge of these polymers also enables them to enter cells
more eﬃciently than naked siRNA.
Lipid based nanoparticles comprise liposomes and lipid nano-
particles (LNPs, Fig. 1b). Liposomes consist of a lipid bilayer with an
aqueous core into which siRNA can be loaded. This is in contrast to
LNPs, which are less structured aggregates of lipid micelles and oligo-
nucleotides. Again, the presence of cationic and protonatable groups is
crucial for mediating the interaction with the plasma membrane and
delivery of encapsulated oligonucleotides. In addition, strategies such
as dendrimers, mesopourous silica nanoparticles, and microbubbles will
be discussed (Fig. 1c–e).
Although the molecular make up of nanoparticles can vary greatly,
they are all characterized by the capacity for further functionalization.
These carriers of increasing complexity aim at enhancing cell type se-
lectivity, uptake eﬃciency, anticancer activity and circulation time [6].
Polyethylene glycol (PEG) is the most frequently used shielding agent to
increase circulation time and avoid recognition by the immune system
[10]. Targeting moieties include for example antibodies or small mo-
lecules such as folate. Cellular uptake eﬃciency can furthermore be
enhanced by using cell-penetrating peptides [11–13].
Unfortunately, there has still been no translation of siRNA-mediated
gene targeting into the clinic despite extensive preclinical research and
the urgent medical need. We identify several potential drawbacks of the
current state-of-the-art and try to explain why these inhibit further
development into a clinically applicable therapy. We argue that the
sheer abundance of delivery strategies and the lack of cross validation
between these methods stalls further development of siRNA delivery
systems in ovarian cancer.
There seems to be a tendency towards increasingly complex delivery
systems instead of identifying the minimal platform for reaching suﬃ-
cient activity. The same holds for the choice of the siRNA target. A
number of genes has been targeted for knockdown, but no research is
devoted towards reaching a consensus as to which target would even-
tually have the strongest potential in the clinic.
2. Polymer based nanoparticles
2.1. Polyethyleneimine (PEI) based nanoparticles
Polyethyleneimine (PEI) based nanoparticles have been widely used Ta
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for siRNA delivery (Table 1) [14]. PEI is a cationic polymer consisting
of a repeating amine and ethyl unit. This polymer can spontaneously
form condensed nanocomplexes (polyplexes) via electrostatic interac-
tions with the anionic backbone phosphates of siRNA, which vary in
size from 100 to 1000 nm, [15]. The ratio between the number of
charges in the formulation is known as the amine/phosphate (N/P)
ratio. The molar ratio of polymer/siRNA is mostly selected in a way that
cationic groups are present in excess (N/P > 1), resulting in net po-
sitively charged nanoparticles. Furthermore, due to the complexation,
siRNA is protected from enzymatic degradation and cellular uptake by
endocytosis is promoted [16].
Endosomal escape is a major obstacle for all nanoparticles that enter
cells via endocytosis [17]. siRNA that is captured inside endosomes does
not reach its molecular target and will ultimately be degraded. PEI
based nanoparticles overcome this problem by inducing a process called
the proton sponge eﬀect [15]. The amines of PEI bind protons in the
lysosome and the persistent inﬂux of protons and charge-neutralizing
chloride ions causes an increase in osmolarity. This leads to water inﬂux
and ultimately to rupture of the lysosomal membrane and release of its
content into the cytosol [18].
Although PEI shows high transfection eﬃciency, this non-biode-
gradable polymer is also cytotoxic at higher concentrations [19]. A
correlation of higher transfection eﬃciency with higher cytotoxicity is a
problem of many cationic transfection agents as exempliﬁed by high
molecular weight PEI [20]. To reduce toxicity in potential clinical use,
PEI is functionalized with other molecules or polymers such as PEG. In
addition, longer circulation time, as aﬀorded by PEGylation, can in-
crease nanoparticle accumulation in a tumor through the enhanced
permeation and retention (EPR) eﬀect, which means that macro-
molecular compounds exit the leaky tumor vasculature and remain
trapped in the tumor microenvironment [21–24].
Unfortunately, along with reducing toxicity, PEGylation also de-
creases transfection eﬃciency of PEI polyplexes and other nanoparticles
[10,25]. Other strategies to decrease cytotoxicity while maintaining
transfection eﬃciency have therefore been developed and include
combining PEI and PEG with other molecules. The ﬁrst option is the
addition of hyaluronic acid (HA) to both molecules [26,27]. The con-
jugation of PEI with HA results in electrostatic neutralization of the
nanoparticles due to the negative charge of HA. Also, HA contributes to
the formation of a protective hydrophilic surface. This polysaccharide
furthermore speciﬁcally binds to CD44 and can therefore be used as a
targeting agent to increase cell speciﬁcity. CD44 is a cell-surface gly-
coprotein that is, among other functions, involved in cell-cell contacts,
cell migration, angiogenesis, and cell survival [28]. The protein is often
upregulated in ovarian cancer, although there is still debate on its
function and association with prognosis [29–31].
Talekar et al. [26] and Yang et al. [27], used such nanoparticles loaded
with siRNA to target expression of the Multi Drug Resistance Gene 1 (MDR1),
which codes for P-glycoprotein (P-gp), in combination with paclitaxel treat-
ment. Almost 90% of deaths in advanced stage ovarian cancer is linked to
MDR, and the major contributing factor is MDR1 overexpression [32–34].
Furthermore, combined CD44 and MDR1 expression correlates with
progressive EOC [35]. Therefore, Yang et al. [27] used an siRNA against
MDR1 in combination with paclitaxel in order to downregulate P-gp
and thereby increase chemosensitivity [27]. In vitro, a dose dependent
downregulation of P-gp expression was shown on mRNA and protein level.
Furthermore, paclitaxel sensitivity increased in both, in vitro and in vivo
models. However, HA targeting was only assessed in CD44 expressing cells,
without a non-CD44 expressing control.
Talekar et al. combined siRNA against MDR1 with a second siRNA
against pyruvate kinase isozyme M-2 (PKM-2) [26]. This enzyme con-
verts phosphoenolpyruvate into ATP and pyruvate in glycolysis. It is
expressed in cells with a high rate of nucleic acid synthesis such as
tumor cells [36]. By targeting two important cancer-related pathways,
the authors showed that the eﬃcacy of paclitaxel against MDR EOC was
improved compared to targeting of MDR1 alone [26]. Even thoughTa
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CD44 was used as a cell speciﬁcity target, the authors did not assess
CD44 expression on the model SK-OV-3 cells. In vivo, siRNA uptake was
highest in the liver, kidney, and spleen. Gene knockdown was only
tested in the tumor and not in other organs. Whereas the tumor only
showed minor uptake tumor volume was smaller compared to control
mice.
Teo et al. combined PEI with PEG and folic acid (FA) [21]. The
folate receptor α (FRα) is overexpressed in the majority of EOCs and is
therefore widely studied for speciﬁc ovarian cancer cell targeting [37].
Furthermore, FA is little immunogenic, inexpensive, and stable under
cellular conditions [23,38]. To improve siRNA transfection, a disulﬁde
bond was introduced between PEG-FA and PEI that made the polymers
cleavable in the cytosol [21]. Diﬀerent combinations of PEI based na-
noparticles were used: PEI, PEI-FA, PEI-PEG, and PEI-PEG-FA. N/P ra-
tios between 10 and 80 were studied and higher transfection eﬃ-
ciencies were observed with increased N/P ratios. A decrease in protein
expression was observed for the PEI and PEI-FA nanoparticles at N/P
ratios of 50 and 80. With a downregulation by 45 to 49%, these
transfections were more eﬃcient than those of PEI-PEG and PEI-PEG-
FA, which showed eﬃciencies of 35–38% at the same N/P ratio.
However, cell viabililty decreased by 20% at an N/P ratio of 50 and by
40% at an N/P ratio of 80. PEI nanoparticles showed even more toxi-
city, respectively 40 and 60% [21]. To enhance an immune response
against the tumor, the authors used siRNA against PD-L1. The inter-
action between programmed cell death protein 1 (PD-1) and its ligand
PD-L1 accounts for T cell hyporesponsiveness in epithelial ovarian
cancers resulting in a suppressed local immune response [39–41].
Therefore, a co-incubation with T4 engineered T cells was performed.
These T cells were engineered to co-express the chimeric antigen re-
ceptor (CAR, T1E28z), and targeted the extended ErbB family. T4 en-
gineered T cells showed potent cytoxicity against ovarian cancer cells
that had shown upregulated expression of the HER2/neu receptor in an
earlier study [42]. Co-incubation of T cells with siRNA against PD-L1
resulted in an additional decrease of cell viability by roughly 10%
compared to T cell incubation alone [21].
As a more complex formulation, a triblock polymer of PEI-poly-
caprolactone-PEG (PEI-PCL-PEG) with FA as a targeting moiety coupled
to PEG was developed (Fig. 1a) [43]. PCL yielded biodegradability and,
due to its hydrophobic nature, was used as the hydrophobic core of the
self-assembled nanoparticles (Fig. 2c). The PEI-PCL-PEG triblock
polymer retained siRNA better than PEI in the prescence of heparin,
demonstrating an improved encapsulation eﬃciency. In contrast, the
triblock polymer showed a more eﬃcient heparin-induced release at
pH 4.5. According to the authors, this indicates that siRNA release in
endosomes would be higher compared to PEI nanoparticles. An siRNA
against toll-like receptor 4 (TLR4) was used in this study in combination
with paclitaxel. Previous studies had suggested that upregulation of
TLR4 results in chemoresistance, which was reversed by siRNA in this
study [43–46].
Zou et al. used a similar polymer, albeit with a diﬀerent arrange-
ment of the polymer blocks (FA–PEG–PEI–PCL) combined with a che-
motherapeutic next to siRNA [47]. Bcl-2 was targeted in an eﬀort to re-
sensitize cells to doxorubicin. Bcl-2 is an apoptotic inhibitor that is
upregulated in ovarian cancer, which results in decreased sensitivity to
most cytotoxic agents [48]. Doxorubicin was incorporated into the
nanoparticles in order to reduce side eﬀects. Furthermore, to decrease
the cationic toxicity of PEI, low molecular weight linear PEI instead of
high molecular weight hyper-branched PEI was used.
Li et al. used a PEG-PLL-PEI triblock polymer in which PCL was
replaced by poly-L-lysine (PLL) [22]. Like PEI, PLL has a high charge
density that can be used for siRNA complexation. However, similar to
PCL, PLL is biodegradable thereby increasing the degradation of the
ternary copolymer. In this cases the inhibitor of apoptosis protein
(XIAP) was targeted, which is upregulated in ovarian cancer SK-OV-3
cells [22]. To enhance selective delivery, a trastuzumab single chain
antibody that targets the HER2/neu receptor was added. In spite of the
fact that this receptor is overexpressed in SK-OV-3 cells, the number of
HER2/neu positive ovarian tumors is low and its prognostic sig-
niﬁcance is controversial [22,49–51]. The targeted nanoparticles
showed enhanced tumor uptake in nude mice with a subcutaneous
tumor [22]. Still, the majority of the nanoparticles distributed to the
liver. Nevertheless, the tumor showed necrosis in mice that were
treated with nanoparticles containing siRNA against XIAP at N/P 20,
while the other organs were unaﬀected. 90% of the mice in the targeted
Table 5
Characteristics of silicon based nanoparticles.
Article NP composition Size (nm) Zeta
potential
(mV)
siRNA
target
Chemotherapeutic Cell line in
vitro
Murine
model
Cell line
in vivo
Tumor site Drug
administration
Shen [86] DOPC NPs in
silicon
microparticles
1000×400
(30–35
liposome)
3–7 EphA2 IP paclitaxel or
docetaxel
SK-OV3ip2,
HeyA8-
MDR
Female
nude
BALB/c
SK-OVip2,
HeyA8-
MDR
IP IV
Chen [85] M-MSN-PEI-PEG-
KALA
160 23 VEGF None SK-OV-3 Female
nude
BALB/c
SK-OV-3 SC for xenograft
formation,
intraovarian for
experiments
IV
DOPC, 1,2-Dipalmitoyl-sn-glycero-3-phosphorylcholine; M-MSN, mesoporous silica nanoparticles; PEI, polyethyleneimine; PEG, polyethylene glycol; EphA2, ephrin
type-A receptor 2; VEGF, Vascular endothelial growth factor; N/A, not available – information not included in the corresponding article; SC, subcutaneous; IV,
intravenous; IP, intraperitoneal.
Table 6
Characteristics of microbubble based nanoparticles.
Article NP
composition
Size (nm) Zeta potential
(mV)
polymer:siRNA
ratio (w/w)
Targeted
receptor
siRNA
target
Chemotherapeutic Cell
line in
vitro
Murine
model
Cell
line in
vivo
Tumor site Drug
administration
Florinas [93] PCE-
albumin-
ABP
3001 −34.6 ± 5.4 10:1 None VEGF None A2780 N/A N/A N/A N/A
Florinas [92] Female
nude
mice
A2780 SC IT
PCE, perﬂuorocrownether; ABP, arginine grafted polymers; VEGF, vascular endothelial growth factor; N/A, not available – information not included in the corre-
sponding article; SC, subcutaneous; IT, intratumoral.
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group survived> 45 days, whereas none of the control animals sur-
vived this long.
Another triblock approach for combination therapy of siRNA and
doxorubicin was based on reducible micelles consisting of PEG-pAsp
(AED)-PDPA [52]. Doxorubicin was loaded into the pH sensitive poly(2-
(diisopropyl amino)ethyl methacrylate) (PDPA) core. siRNA against
Bcl-2 was loaded in the reduction sensitive middle layer of poly(N-(2,2′-
dithiobis(ethylamine)) aspartamide (PAsp(AED)), and PEG formed the
corona that stabilized the particles. Because these nanoparticles did not
contain PEI, they relied on a diﬀerent mechanism to induce endosomal
escape. The particles were designed to be stable in the bloodstream but
to disassemble and release their contents at low pH and high glu-
tathione concentrations as present in lysosomes and cytosol, respec-
tively [52]. In vitro experiments showed that the particles indeed re-
leased their contents at a pH of 5.0 and high glutathione concentration
(Fig. 2a). Biodistribution experiments revealed that particle uptake
occurred mainly in the tumor and liver and that they were retained
there for at least 24 h. Clear synergistic eﬀects of siRNA and doxor-
ubicin were shown in vitro and in vivo. However, only the tumor and no
other organs was assessed for structural abnormalities and apoptotic
markers after the in vivo experiments.
2.2. Polysaccharide based nanoparticles
Chitosan is a natural cationic polysaccharide that is composed of
D-glucosamines and can readily form nanoparticles through electro-
static interactions with oligonucleotides (Table 2, Fig. 1a) [53]. Li et al.
used these features to create nanoparticles that consisted of chitosan
oligosaccharide lactate (COL) in combination with tripolyphosphates
(TPP) as a counterion [23]. The particles remained highly cationic
despite the counterion, which resulted in interaction with red blood
cells, opsonization, and activation of the immune system that led to
Fig. 1. Examples of the drug delivery systems that are discussed in this review. A Polymeric nanoparticles, with a triblock copolymer on the left and a chitosan based
nanoparticle on the right. A triblock copolymer typically consists of a hydrophobic unit followed by a corona of a hydrophilic unit. This part is mostly cationic and
can bind siRNA through electrostatic interactions. The outermost layer consists of a polymer, such as PEG, that shields the nanoparticles from the immune system and
prolongs circulation time. Chitosan nanoparticles are less organized and form an amorphous complex of polymer chains to which siRNA binds through electrostatic
interactions. B Lipid based nanoparticles with a liposome on the left and a lipid nanoparticle (LNP) on the right. Liposomes consist of a lipid bilayer and siRNA is
entrapped in the aqueous core. Variation of the phospholipid composition alters the net charge and stability of the liposome. Also, compounds like cholesterol are
often added to increase stability. LNPs consist of (inverted) micelles that co-aggregate with siRNA. C Dendrimeric nanoparticles are composed of a core from which
branched polymers extent outwards from several branching points. Each additional layer is called a generation. D Mesoporous silica nanoparticles are large particles
with pores in which diﬀerent, smaller nanoparticles can be loaded. In this example, lipid particles are loaded into the pores. E Microbubbles are gas ﬁlled nano-
particles with a shell that can consist of a range of diﬀerent materials. When ultrasound is applied, the bubble bursts, and the polyplexes that encapsulate siRNA will
enter the cells through temporal perforations in the plasma membrane and microjets that forces the siRNA into the cells.
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elimination of the nanoparticles. To reduce surface charge and thereby
increase circulation time, the nanoparticles were PEGylated. Targeting
to ovarian cancer cells was achieved by functionalizing PEG
with FA yielding FA-PEG-COL that was used to form nanoparticles
containing siRNA against the hypoxia-inducible factor-1α (HIF-1α).
Expression of HIF-1α is often higher in ovarian cancer and is associated
with various aspects of cancer progression, like angiogenesis, cell
migration, proliferation, survival, metastasis, and drug resistance and
could therefore be a prognostic marker [54].
Gharpure et al. also used TPP chitosan with an siRNA against the
Enhancer of Zeste Homolog 2 (EZH2) [55]. Overexpression of EZH2 is
associated with a more proliferative and aggressive phenotype [56]. In
this study, TPP chitosan siRNA nanoparticles were combined with
docetaxel-loaded PLGA-PRINT (PLGA -Particle Replication In Non-
wetting Templates) nanoparticles. PRINT is a method based on soft li-
thography that enables adjustment of particle parameters like size,
shape and composition [57]. This formulation allowed for metronomic
dosing of docetaxel. In metronomic dosing, the chemotherapeutic is
administered more frequently in a lower dose to obtain a more constant
concentration [58]. The PLGA-PRINT nanoparticles were rod shaped
with a size of 80× 320 nm and a polydispersity index of 0.159. The
authors tested metronomic dosing by IP injections of either free doc-
etaxel or docetaxel loaded nanoparticles in tumor bearing mice. In a
dose ﬁnding study where siRNA was not included, the experimental
group received 0.5–2mg/kg docetaxel loaded PLGA-PRINT nano-
particles 3 times per week and the control group received 20mg/kg free
docetaxel every two weeks. The tumors of the mice treated with PLGA-
PRINT were slightly but signiﬁcantly smaller than those of the control
group [55]. Subsequently, a combination of docetaxel loaded PLGA-
PRINT nanoparticles with siRNA containing TPP chitosan nanoparticles
was studied in vivo. A decrease in tumor weight was shown for the
combination therapy, compared to loaded PLGA-PRINT and TPP chit-
osan nanoparticles alone. Unfortunately, controls with free docetaxel
and free docetaxel with TPP chitosan siRNA nanoparticels were not
included in these experimets.
Polylactic acid (PLA) can also be combined with chitosan. Babu
et al. used PLA as an inner core loaded with cisplatin [59]. The outer
layer consisted of chitosan ionically complexed to plasmid DNA coding
for the proteasome subunit beta type-5 (PSMB5) and siRNA against
sequestosome-1 (SQSTM1) (Fig. 2c). This combined delivery was used
as proof-of-concept for the hypothesis that simultaneous upregulation
of PSMB5, and downregulation of SQSTM1 would restore drug sensi-
tivity in cisplatin resistant cells. The authors concluded that additional
research on other cell lines had to be performed prior to in vivo studies
with xenograft models [59].
While most polysaccharide nanoparticles were based on chitosan,
Kobayashi et al. utilized dextran functionalized with thiol, PEG, and a
hexylamine or octylamine tail [60]. Hexylamine-dextran was selected
for encapsulation of doxorubicin and octylamine-dextran was used for
production of nanoparticles encapsulating siRNA. Doxorubicin en-
capsulation was supposed to occur by hydrophobic interactions of the
aromatic groups of doxorubicin with the triazol ring present on the
click chemistry-modiﬁed dextran-hexylamine polymers. Higher toxicity
of doxorubicin nanoparticles was shown with an MTT assay and
knockdown of P-gp was conﬁrmed by western blot, but unfortunately,
the combination of both treatments was not studied [60]. Hence the
synergistic eﬀect of a combination therapy is unknown.
3. Lipid based nanoparticles
Most lipid based nanoparticles used for siRNA delivery are lipid nano-
particles (LNPs) and liposomes (Fig. 1b). Liposomes either shield healthy
cells from a toxic compound, as illustrated by PEGylated liposomal doxor-
ubicin (Doxil, Caelyx), or protect encapsulated cargo from degradation and
enhance cellular uptake as for oligonucleotide delivery (Table 3). Liposomes
can vary greatly in their phospholipid composition and additional
Fig. 2. Transmission electron microscopy images of several polymeric for-
mulations. A Morphology of PEI-PCL-PEG-Fol nanoparticles. The left image
shows nanoparticles with a 5 kDa PEG chain, and the right image shows a
sample where a mixture of 3.5 and 5 kDa PEG chains were used. Reprinted with
permission from Jones et al. [43]. Copyright (2016) American Chemical So-
ciety. B Micellar nanoparticles that consist of a PDPA core, a PEG corona, and a
reduction sensitive middle layar of PAsp(AED) in which siRNA against BCL-2
was loaded. The top left image shows unloaded micelles at pH 7.4. The top right
image shows siRNA and doxorubicine loaded micelles (N/P 15). The bottom left
picture shows the same loaded nanoparticles at a pH of 5.0. The bottom right
picture shows the loaded particles at a pH 5.0 in the presence of 10mM GSH.
Reprinted from Chen et al. with permission of John Wiley and Sons under li-
cense number 4341261459831 [52]. C Cisplatin loaded nanoparticles with an
inner core of polylactic acid and a corona of cationic chitosan that was ionically
linked with siRNA against SQSTM1 and plasmid DNA expressing PSMB5. (i)
cisplatin-PLNP, (ii) chitosan–cisplatin-PLNP, and (iii) siRNA-chitosan-cisplatin-
PLNP. Reprinted with permission from Babu et al. [59]. Copyright (2014)
American Chemical Society. PEI, polyethyleneimine; PEG, polyethylene glycol;
PCL, polycaprolactone; Fol, folate; PDPA, poly(2-(diisopropyl amino)ethyl
methacrylate); PAsp(AED), poly(N-(2,2′-dithiobis(ethylamine)) aspartamide;
BCL-2, B-cell lymphoma 2; N/P, amine/phosphate ratio; GSH, glutathione;
SQSTM1 / P62, sequestosome 1 / polyubiquitin-binding protein P62; PSMB5,
Proteasome subunit beta type-5; PLNP, polylactic acid nanoparticle.
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functionalities for targeting, shielding, etc. can be attached via lipid anchors
[61–63]. Preferentially, cationic liposomes are used for intracellular de-
livery of oligonucleotides since these particles readily interact with the
negatively charged plasma membrane of the cell.
In the context of ovarian cancer, Zhao et al., studied a cationic liposome
consisting of a cholesterol derivate N-(cholesterylhemisuccinoyl-amino-3-
propyl)-N, N-dimethylamine (DMAPA-chems) with phosphatidylcholine
(S100 soybean extract) [64]. DMAPA served as a cationic head group and
CHEMS as the hydrophobic moiety [64]. Liposome formulations containing
cationic cholesterol derivatives were shown to be less toxic than other ca-
tionic liposomes [65,66]. The transmembrane protein NOTCH1, which is a
known oncogene [67], was targeted with siRNA in this study [64]. The
DMAPA-cholesterol containing nanoparticles were almost nontoxic at N/P
ratios up to 120, and downregulation of NOTCH1 was roughly equal in
DMAPA-chems transfected cells compared to Lipofectamine control. Fur-
thermore, a small decrease in cell viability after incubation with NOTCH1
siRNA compared to incubation with control siRNA was observed.
A study by He et al., used a more complex drug delivery system that was
based on a zinc bisphosphonate nanoscale coordination polymer (NCP)
containing 48wt% cisplatin instead of an aqueous core [68]. This core was
surrounded by a lipid bilayer of 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA),
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-PEG2k (DSPE-PEG2k). As these particles did
not provide an aqueous core for the incorporation of siRNA, the cationic
phospholipid DOTAP was used to improve cellular uptake and to retain the
siRNA in the corona of the nanoparticle. siRNAs against Bcl-2, P-gp and
survivin were combined to synergistically enhance the eﬀect of cisplatin.
Cisplatin was released through high intracellular cysteine and glutathione
concentrations. Multiple cell lines were employed to analyze the in vitro
eﬀects of the nanoparticles, and SK-OV-3 cells were used to establish a sub-
cutaneous xenograft. Although biodistribution was not studied systematically,
kidney and liver did not show any structural damage after treatment with the
nanoparticles. The tumor, however, showed increased apoptosis and was
much smaller in the treatment group compared to the control groups [68]. In
vivo, only the synergistic eﬀect of the combined siRNA's was assessed without
single siRNA controls.
Besides liposomes, other lipid based delivery systems have been studied.
siRNA was modiﬁed with an N-succinimidyl 3-(2-pyridyldithio)propionate
(SPDP) group at the 3′ end of the sense strand and reversibly conjugated via a
disulﬁde linkage to 1,2-dipalmitoyl-sn-glycero-3-phosphothioethanol (PE-SH)
incorporated into PEG2000-phosphatidylethanolamine (PEG2000-PE) based
micelles [69]. These nanoparticles were subsequently used to assess eﬀec-
tiveness of a combination therapy of an siRNA against survivin with
paclitaxel in a single nanoparticle [69,70]. Survivin is a member of the IAP
family that is involved in MDR and apoptosis inhibition and is upregulated in
most human tumors [68,71]. Disulﬁde conjugation stabilized siRNA against
degradation in vitro [69]. In mice, both siRNA alone and siRNA / paclitaxel
combination therapy showed the most signiﬁcant decrease in survivin
protein expression as analyzed with immunohistochemistry. Combination
therapy furthermore resulted in the lowest tumor weight and volume [70].
Interestingly, nanoparticle treatment with siRNA against survivin without the
addition of paclitaxel also led to a signiﬁcant decrease of tumor volume. The
results of this study were mainly obtained from animal studies without
extensive in vitro data to mechanistically support the evidence derived from
the xenograft models.
Shazad et al. developed reconstituted high-density lipoprotein
(rHDL) solid lipid nanoparticles [72]. With a diameter of 12–18 nm,
these particles were in particular remarkable for their small size. HDL is
an important component of the lipid transport system and promotes
transport of excess cholesterol to the liver for elimination [73]. Re-
constituted HDL (rHDL) particles did not contain all elements of natural
HDL, but consisted of apolipoprotein A-1, phosphatidylcholine, cho-
lesterol, and cholesteryl esters. HDL particles are known to escape the
reticuloendothelial system, resulting in a longer circulation time than
standard cationic lipid formulations [74]. In addition, HDL particles are
internalized into cells via scavenger receptor class B type 1 (SR-B1).
This receptor is mainly expressed in the liver and on most malignant
cells and was therefore selected as a starting point for targeted drug
delivery [74]. In mice, the nanoparticles were mainly taken up by the
tumor and the liver in agreement with the pattern of receptor expres-
sion. Therapeutic eﬃcacy was demonstrated by targeting focal adhe-
sion kinase (FAK) or signal transducer and activator of transcription 3
(STAT3), which are involved in tumor development and progression
[74]. Unfortunately, target gene expression was not assessed in the liver
tissue. But liver function tests (ASAT/ALAT) were performed and these
did not show liver damage [72].
Matsui et al. used Multifunctional Envelope-type Nano Device
(MEND) lipid nanoparticles that contained the pH-sensitive cationic
lipid YSK05. This formulation was used to deliver anti-CD45 siRNA to
peritoneal macrophages (PEMs) [75]. In ovarian cancer, PEMs create a
pro-tumor niche by modifying the tumor microenvironment. As a
consequence, these cells are a potentially interesting therapeutic target
[76]. Particle uptake in PEMs increased 5.5- and 9.2-fold when particle
size increased from 75 nm to respectively 200 and 340 nm. Such an
increase was not observed in other cell types. Enlarging the MEND
nanoparticles to 460 nm, however, did not further increase uptake and
even decreased it slightly. IP administration resulted in the most ef-
fective downregulation of CD45 since larger nanoparticles were unable
to reach PEMs when they were injected IV [75].
Goldberg et al. developed large nanoparticles consisting out of li-
pidoids and siRNA against the DNA repair enzyme poly(ADP-ribose)
polymerase 1 (PARP1). Lipidoids are lipid-like materials consisting of
an amine-containing backbone out of which aliphatic chains extent that
form structures similar to lipids and dendrimers [77,78]. PARP1
knockdown is eﬀective in BRCA1 deﬁcient cells since it induces extreme
genomic instability, causing cell cycle arrest and cell death [77]. The
authors hypothesized that amines in the lipidoids bind siRNA via
electrostatic interactions and that these structures facilitate endosomal
escape upon acidiﬁcation of the lysosomal compartment. Furthermore,
they proposed that the hydrophobic chains interact with membranes,
thus aiding endosomal release [77]. Unfortunately, these hypotheses
were not addressed in this manuscript. The exact mechanism behind the
higher eﬀectiveness of these nanoparticles is therefore unknown. De-
spite that shortcoming, the authors clearly showed that mice bearing a
BRCA1 deﬁcient tumor that was treated with siRNA against PARP1
have an extended life span compared to control mice and mice bearing
a BRCA wild type tumor [77].
4. Dendrimer based nanoparticles
Dendrimers are tree-like polymers of repetitively branched mole-
cules that consist of a core from which branched layers (generations) of
polymer extend outwards (Fig. 1c) [79]. Most dendrimers are based on
amine structures like polyamidoamine (PAMAM), and multilayered
dendrimers consisting of several functional units are common nano-
particle forming macromolecules (Table 4).
A generation 6 PAMAM dendrimer with a triethanolamine (TEA)-
core was used to form nanocomplexes via electrostatic interactions with
siRNA targeting the serine/threonine kinase Akt, a well-known onco-
gene associated with tumor cell survival, proliferation, and invasion
[80]. Co-administration of the 85 nm particles and paclitaxel reduced
tumor size and mortality in tumor bearing mice. However, treatment
was based on intratumoral injection and therefore not representative
for a clinical setting of EOC where the challenge lies in targeting of
micrometastases. Injecting all tumor nodules is not feasible in a clinical
setting.
Engelberth et al. modiﬁed a dendrimer based on enzymatically synthe-
sized glycogen (ESG) [81]. Quaternary ammonium groups were introduced
via an epoxide ring opening reaction with glycidyltrimethylammonium
chloride (GTMA). These polymers bound siRNA targeted to superoxide
dismutase 2 (Sod2) via electrostatic interactions. Based on unpublished
observations that Sod2 is highly expressed in ovarian clear cell carcinomas,
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the authors hypothesized that downregulation of this mitochondrial anti-
oxidant enzyme may lead to increased susceptibility to chemotherapeutically
induced redox damage. Protein downregulation with the ESG nanoparticles
was demonstrated on western blot. RNAiMAX Lipofectamine mediated
delivery was more eﬀective in inducing protein downregulation. However,
RNAiMAX also was more cytotoxic, although this experiment was only
performed once. Unfortunately, the authors did not test the hypothesis if
the downregulation of Sod2 indeed causes higher susceptibility to ROS
production by chemotherapeutic agents.
Shah et al. used modiﬁed polypropyleneimine (PPI) dendrimers in
which siRNA was complexed by electrostatic interactions and a cage of
dithiol containing cross-linkers was used to stabilize the complex [82].
Aggregation was prevented by PEGylation and a synthetic gonado-
tropin-releasing hormone (GnRH) analogue was coupled for speciﬁc
targeting to cancer cells. Paclitaxel was coupled to a similar PPI den-
drimer via a biodegradable succinic acid spacer and co-administered
with the siRNA nanoparticle. siRNA was released in the reductive en-
vironment inside the cell and targeted at downregulating CD44 [82]. As
one of few studies, the authors analyzed both uptake and eﬀectiveness
in diﬀerent organs. They showed that the majority of untargeted na-
noparticles ended up in the tumor, although this still represented<
50% of the nanoparticles. Furthermore, a signiﬁcant amount reached
the liver, kidneys, lungs, and heart [82]. With a targeting ligand,
however,> 75% of the nanoparticles distributed to the tumor and only
a minor fraction was retained in the liver. Targeted nanoparticles
loaded with paclitaxel or with paclitaxel and siRNA showed greatly
increased apoptosis in the tumor and decreased toxicity in other organs
compared to untargeted nanoparticles and paclitaxel alone. Apoptosis
was in this case analyzed by the enrichment of histone-associated DNA
fragments per gram tissue. Combination therapy of paclitaxel and
siRNA was the most eﬀective in the apoptosis assay, and when the
tumor volume was measured.
A radically diﬀerent approach was developed by Huang et al., in
which DNA based dendrimers were coupled to folate for targeting, and
hybridized to siRNA against the mRNA-binding protein HuR. HuR sta-
bilizes mRNA molecules and inﬂuences translation of growth-related
mRNAs that are important for multiple stress induced survival path-
ways [83,84]. Multiple signaling pathways were aﬀected by the siRNA
by this broad approach. Biodistrubution was analyzed after IV injection
of the nanoparticles, whereas eﬃcacy was studied after IP injection.
Eﬃcient delivery and increased median survival from<30 days to
roughly 45 days was demonstrated in a xenograft mouse model. In spite
of this success, the therapy was not suﬃcient to eradicate the whole
tumor and cure the animals. Therefore, the authors proposed to com-
bine an siRNA against HuR with chemotherapy or another siRNA [83].
5. Silicon based nanoparticles
The aforementioned formulations can be loaded into mesoporous
silicon nanoparticles (MSNs) in order to achieve slow and sustained
release of siRNA (Fig. 1d). These silicon particles are several micro-
meters in size, and have pores ranging from 1 to 50 μm (Table 5)
[85,86].
In a study of Shen et al., MSNs were loaded with dioleoyl phos-
phatidylcholine (DOPC) based liposomes containing siRNA against the
ephrin receptor A2 (EphA2) [86]. This epithelial protein-tyrosine ki-
nase receptor is often overexpressed in ovarian cancer and is associated
with increased angiogenesis, metastasis, and decreased survival
[87,88]. “Nanoliposomes” were prepared by reconstituting a lyophi-
lized mixture of siRNA and lipids with water. The resulting particles
were retained in the 40–65 nm pores of discoidal porous silicon parti-
cles of roughly 1000×400 nm in size, creating a multistage vector
system. The silicon particles were modiﬁed with 3-aminopropyl-
triethoxysilane (APTES), which converted the surface charge from ne-
gative to slightly positive. This modiﬁcation also enhanced loading of
the neutral to slightly anionic liposomes. Despite of their size, tumor
accumulation of these MSNs was still observed which was attributed to
the discoid shape [86,89]. The authors claim that multiple MSNs were
detected inside the cells even though only the siRNA was ﬂuorescently
labeled. siRNA induced EphA2 knockdown for up to 9 days. Western
blot, however, showed that a scrambled siRNA also knocked down
EphA2 expression at this time point [86]. In the biodistribution study,
the MSNs and the siRNA were separately labeled. Over a course of 12 h
to one week, ﬂuorescence from MSNs could be detected in the kidney
and the liver, whereas ﬂuorescence arising from the tumor disappeared
within 24 h. The authors suggest that high ﬂuorescence in the kidney
resulted from the cleavage of the ﬂuorescent dye from the MSNs [86].
The labeled siRNA on the other hand, was mainly found in the tumor
and the kidney, and could still be detected above background after one
week. The authors propose that the MSNs were stored in the liver as a
depot and that the liposomes were released from there from where they
reached the tumor by the EPR eﬀect [86].
MSNs can also be loaded with naked oligonucleotides. Chen et al.
used magnetic mesoporous silica nanoparticles (M-MSN) consisting of
an Fe3O4 core and a mesoporous silica shell that showed a large loading
capacity of siRNA against VEGF [85]. Since both siRNA and M-MSN
particles were negatively charged, siRNA adsorption was only eﬃcient
in a strongly dehydrated environment [90]. After loading, the particles
were coated with PEI to enhance oligonucleotide binding in an aqueous
solution. This prevented siRNA from premature desorption [85,90].
Furthermore, PEG-KALA, where KALA refers to the peptide WEAKLA-
KALAKALAKHLAKALAKALKACEA, was conjugated to the particles,
which improved cellular uptake and promoted escape of the nano-
particles from lysosomes [85]. The superparamagnetic Fe3O4 core of
the nanoparticle was also used as a contrast agent for magnetic re-
sonance imaging (MRI). Due to this theranostic combination of func-
tionalities, these MSNs provide the possibility to determine and opti-
mize the dose and eﬀectivity in clinical applications [85].
6. Microbubble based nanoparticles
Microbubbles in combination with ultrasound are a strategy for
stimulus-triggered drug release. Microbubbles consist of a gas ﬁlled
core with a shell that can be composed of proteins, surfactants, lipids,
polymers, or a combination thereof (Fig. 1e) [91]. Similarly to MSNs,
microbubbles are typically much larger than nanoparticles and can be
as large as red blood cells [91]. Microbubbles are often used as contrast
agents for imaging, but they can also be employed as drug delivery
vehicles (Table 6). Because oligonucleotides do not dissolve in gas, they
are incorporated in the shell. Upon ultrasound exposure at the target
site, the gas core starts to oscillate, which results in disruption of the
shell. This mechanism induces uptake in two, mutually enhancing
ways. First, the ultrasound temporarily perforates cells, which allows
the entrance of siRNA. Second, the force with which the bubble bursts
causes microjects that force the siRNA directly into the cells [92,93].
Microbubbles of 3 μm in diameter with an albumin shell and a
perﬂuorocrownether (PCE) gas core were loaded with an arginine
grafted polymer (ABP), a disulﬁde linked polyamidoamine backbone
with arginine functionalities. These ABPs formed stable polyplexes
of< 200 nm with siRNA directed against VEGF, and loading occurred
trough electrostatic interactions of the anionic microbubbles and ca-
tionic ABPs [93]. The arginine residues increased transfection eﬃ-
ciency and endocytosis of the polyplexes. siRNA was released into the
cytosol when the disulﬁde amine backbone was reduced by in-
tracellular glutathione [93,94]. These nanoparticles showed higher
transfection eﬃciency than 25 kDa branched PEI. In 2014, Florinas
et al. conﬁrmed improved siRNA uptake in vivo in a subcutaneous
murine ovarian cancer model [92]. A subcutaneous xenograft was used
in this study and an ultrasound probe was placed directly on the tumor.
Unfortunately, this method is not clinically feasible since ovarian
cancer resides in the abdominal cavity. The ultrasound should in this
case either be applied to the whole abdomen or to every individual
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metastasis, and this should also include small tumor deposits invisible
to the naked eye.
Ultrasound triggered lipid microbubbles have also been applied for
GnRH and FRα targeted intraperitoneal delivery of paclitaxel [95,96].
Eﬀectiveness was assessed in an IP xenograft model. However, the
whole abdomen was subjected to ultrasound. This could also induce
paclitaxel release from the microbubbles that are not bound to the
tumor, thereby reducing speciﬁcity. It therefore remains to be shown to
which degree this approach is also viable for the systematic eradication
of cancer micrometastases in the much larger human abdominal cavity.
7. Discussion
7.1. Nanoparticle design
A large diversity of carriers and cargos has been explored for siRNA
delivery to ovarian cancer. Nearly all approaches have in common that
they incorporate the anionic siRNA via non-covalent complexation with
the cationic carrier. Furthermore, the net positive charge of these par-
ticles also promotes cellular uptake. The complexation method was
diﬀerent in only three studies. In the ﬁrst study, PEG2000-PE micelles
were reversibly conjugated to a modiﬁed siRNA against survivin
[70,97]. The second study utilized DNA based dendrimers that hy-
bridized siRNA to one of the single-stranded sequences of the dendrimer
[83], and the third study used mesoporous silica nanoparticles in which
naked siRNA was loaded under hydrophobic conditions [85].
Starting from the fundamental design of a non-covalent poly−/li-
poplex, diversity and complexity are introduced through (i) structural
variation of the carrier and inclusion of shielding in the form of
PEGylation, (ii) incorporation of targeting modalities, (iii) variation in
size, and (iv) means to promote intracellular disassembly. Two more
variables are introduced through variation of the siRNA target and the
combination of siRNA with standard chemotherapeutics. These latter
two variables are not fully independent of one another as some siRNAs
target genes to achieve a resensitization of cancer cells to che-
motherapy.
Many formulations rely on a high N/P ratio to incorporate siRNA
into the particles. An excess of amines results in a net positive charge of
the particle. Fundamental for the evaluation of a carrier is the balance
between activity and toxicity and in many cases, increased uptake ef-
ﬁciency comes along with a higher risk of toxicity as is shown for PEI
based siRNA delivery. Shielding in the form of PEGylation is therefore a
common method to reduce this cytotoxicity. Unfortunately, the eﬀects
of siRNA delivery and nanoparticle toxicity in healthy tissues are often
not studied well. Some articles investigate structural damage on his-
tological sections, but this is only a crude assessment of the damage.
The eﬀects of cationic damage and protein downregulation by siRNA
can be more subtle and this should therefore be assessed in healthy
organs as well as in the tumor [98].
In order to enhance speciﬁc tumor cell targeting, targeting mod-
alities are often incorporated into the nanoparticle formulation. A
common receptor for active targeting in ovarian cancer is the folate
receptor alpha. FRα is overexpressed on the majority of ovarian tumors,
and can be targeted with antibodies or FA [23,38]. However, following
IP injection entry of intact delivery vehicles into systemic circulation
has to remain limited since the receptor is also present in healthy tis-
sues. Several FRα targeting candidate drugs are being tested in clinical
trials [37], but unfortunately, some have failed despite initial promising
results [99].
Independent of the presence of targeting ligands, accumulation of
nanoparticle formulations for EOC therapy in the liver is a concern even
after IP administration [26,52,68,82,86]. Following IP administration,
Shah et al. saw<50% of the polypropyleneimine (PPI) dendrimers
accumulating in the tumor and> 25% in the liver [82]. Adding an
active targeting ligand against GnRH improved biodistribution and
resulted in a tumor accumulation of> 75%. Also, apoptosis was much
higher in the tumor than in the liver and kidneys. Shahzad et al. also
observed signiﬁcant liver uptake of rHDL particles targeting scavenger
receptor B1. However, they did not observe signiﬁcant diﬀerences in
biodistribution and uptake when IV and IP administration were com-
pared [72]. This included the tumor and the liver. It should nonetheless
be noted that the hepatic accumulation seemed to be higher upon in-
travenous administration compared to intraperitoneal administration.
Even though this was not a signiﬁcant increase according to the mi-
croscopy image analysis.
Polymer and lipid based formulations vary in size between 20 and
250 nm. Formulations such as microbubbels and MSNs on the other
hand, are much larger and can reach sizes of up to several micrometers.
A larger size can be a preferred characteristic for IP therapy of ovarian
cancer since larger particles are expected to be retained in the in-
traperitoneal cavity for quite some time before entering the blood
stream. Matsui et al. compared IV with IP administration in dependence
of particle size [75]. They concluded that particles with a size of
75–340 nm were able to transfect macrophages in the peritoneal cavity
after IV injections. However, nanoparticle uptake in these cells corre-
sponded to only 0.1% of the total injected dose and most of the particles
ended up in the liver. The authors furthermore showed that IP injection
achieved eﬃcient gene knockdown at an siRNA dose that was 330 times
lower compared to IV administration [75]. However, in ovarian cancer,
the intraperitoneal cavity can be ﬁlled with ascites, a protein and lipid
rich ﬂuid that contains blood and tumor cells that may sequester par-
ticles and thus limit bioavailability [100]. Also, nanoparticle avail-
ability could be restricted by the extracellular matrix and absence of
entry into the tumor-perfusing vascularization [101]. Therefore, sys-
tematic studies are required to better understand to which degree na-
noparticles can enter the tumor stroma from the peritoneal side.
As intraperitoneal retention increases with size, the use of micro-
meter sized silicon particles can be interesting since these combine long
half-life with their slow-release ability. Under physiological conditions,
MSNs are degraded into silicic acid, which is eliminated by the kidney
or deposited into connective tissues [102]. Silicon is the third most
abundant trace element and ortho-silicic acid is linked to some ther-
apeutic eﬀects [103]. This indicates that low levels of silicon will
probably not cause cytotoxic eﬀects.
7.2. siRNA design
Two types of siRNA targeted pathways can be discriminated: Those
relating to drug resistance and cell survival, and those relating to tumor
growth and angiogenesis (Fig. 3). The most common targets in EOC
tharpy are MDR genes and genes involved in cell survival, MDR1, Bcl-2
and survivin (Tables 1–6). Downregulation of these genes resensitizes
the cells to chemotherapy and siRNAs targeting these pathways are
always combined with chemotherapeutic treatment. This combination
has been applied in almost half of the discussed studies and in all na-
noparticle formulations except microbubbles (Tables 1–5). One excep-
tion in which siRNA against MDR1 was tested without the addition of
chemotherapy is the publication of Kobayashi et al. [60].
VEGF and FAK are the most common targets regarding cell migra-
tion, proliferation, and angiogenesis. Other prominent siRNA targets
were CD44 and EphA2 that are both involved in angiogenesis.
Interestingly, CD44 was more often used as a receptor for active tar-
geting than as an siRNA target. Two studies utilized a combination of
more than one siRNA. Both contained an siRNA directed against MDR1.
He et al. also targeted Survivin and Bcl-2, whereas Talekar et al. ad-
dressed PKM-2 [26,68]. These strategies aimed at reducing the chance
of survival through upregulation of escape pathways. Furthermore, one
study combined siRNA therapy against the ubiquitin binding protein
P62 with transfection of a plasmid that encoded for the β5 subunit of
the 26S proteasome complex, causing an interplay between restored β5
function and P62 knockdown that resensitized cells for cisplatin [59].
In addition, some studies aimed at reducing the systemic toxicity of
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chemotherapeutics by also encapsulating them in nanoparticles with or
without a targeting moiety (Tables 1–6).
At this point it is still not clear which (combination of) targets are
the most promising for clinical application. Clearly, some targets, for
example HER2/neu, seem less likely to succeed due to low expression in
ovarian cancer [49].
7.3. Clinical applicability
For clinical application, reproducibility and cost eﬃciency are also
considerations when designing new formulations. These boundary
conditions favor simple designs that incorporate the minimal set of
functionalities for achieving a therapeutic beneﬁt. Interestingly, there
was nearly no cross-referencing between diﬀerent approaches in the
reviewed literature. Therefore, also the beneﬁt of an additional func-
tionality is diﬃcult to assess.
Liposomes are expensive to manufacture and oligonucleotides need
to be encapsulated in the form of polymer-complexed nanoparticles.
The potential advantage is the versatile surface functionalization.
However, LNPs provide very similar possibilities with a more straight-
forward overall design (Table 4). Polymer-based nanoparticles combine
a good shelve life with sustained release but this may also restrict the
bioactive concentration. No polymer-based oligonucleotide formulation
has made it into the clinic so far, even though PEI toxicity can be de-
creased by the addition of PEG and less toxic alternatives such as
PAMAM-based polymers have been explored. As mentioned above,
mesoporous silica nanoparticles are an interesting option for taking
advantage of retention in the intraperitoneal cavity and for inducing
sustained release of bioactive nanoparticle formulations. Moreover,
ultrasound-triggered microbubbles overcome problems such as siRNA
entrapment and ineﬃcient release from the delivery vehicle, which are
common to polymer-based delivery systems and liposomes. However,
the eﬀectiveness of this approach for the large human peritoneal cavity
remains to be shown.
7.4. Methodological considerations
Methodological diﬀerences of the presented studies also complicate
the identiﬁcation of the most promising system for clinical use. The
large majority of studies based their conclusions on tests with a single
Fig. 3. Receptors for active targeting and siRNA targets discussed in this review. Receptors for active targeting are shown on top. Several targeting moieties were
used to induce cell speciﬁc nanoparticle uptake. Some active targeting strategies incorporated the respective ligand such as folate for the folate receptor and GnRH for
the GnRH receptor. Antibodies have also been used widely, and sometimes the inherent properties of the nanoparticle formulation showed preference for certain
receptors. Hyaluronic acid for example binds to CD44, and rHDL nanoparticles are taken up by the Scavenger-Receptor B1. All siRNA targets are shown inside the cell
and on the bottom part of the plasma membrane. All intracellular targets are shown as rounded rectangles. Ellipses relate to factors that link these targets. These were
included to indicate the connection of various pathways. Several studies interfered with apoptosis inhibiting pathways (yellow). Others addressed the PI3K/AKT/
mTOR pathway (green), DNA repair and replication (blue), and cellular metabolism (pink). Some studies intended to alter the tumor microenvironment by
downregulating certain receptors like VEGF, CD44, TLR4, and Epha2. Also, several studies down regulated P-gp expression in order to overcome drug resistance, and
PD-L1 was targeted in order to induce an immune reaction. Akt, protein kinase B; CLDN3, claudin-3; Epha2, ephrin receptor A2; FAK, focal adhesion kinase; GnRH,
gonadotropin-releasing hormone; HER2/Neu, receptor tyrosine-kinase erbB-2; HIF1a, Hypoxia-inducible factor 1-alpha; HuR, ELAV-like protein 1; mTOR, me-
chanistic target of rapamycin; P62 / SQSTM1, polyubiquitin-binding protein P62 / sequestosome 1; PARP1, poly ADP ribose polymerase 1; PDK1, Pyruvate de-
hydrogenase lipoamide kinase isozyme 1; PD-L1, Programmed death-ligand 1; P-gp, p-glycoprotein; PI3K, Phosphatidylinositol-4,5-bisphosphate 3-kinase; PKM2,
Pyruvate kinase isozymes M2; SOD2, Superoxide dismutase 2; SR-B1, scavenger receptor B1; STAT3, Signal transducer and activator of transcription 3; TLR4, toll like
receptor 4; VEGF, vascular endothelial growth factor; XIAP, X-linked inhibitor of apoptosis protein.
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cell line, whereas only a few studies used multiple cell lines to validate
their drug delivery system. The most widely used cell lines are well
characterized, so speciﬁc mutations are known. However, in spite of
their frequent use, the cell lines SK-OV-3 and A2780 are poorly suited
as models for high-grade serous ovarian cancer since their genetic
ﬁngerprint is very diﬀerent from primary tumors [104]. Therefore,
results obtained with these cells should be validated with more reliable
ovarian cancer models. The likelihood that a therapy will be applicable
in the clinic will generally increase when it is validated with various
ovarian cancer cell lines.
Monolayer cell culture models can give fundamental information on the
working mechanism of nanoparticles. These simple models, however, do
not recapitulate the complex situation of a clinical tumor. They lack a 3D
arrangement of cells, stroma, other cell types, and ﬂuid ﬂow. These factors
can greatly alter the bioavailability and eﬀectiveness of nanoparticles.
Penetration of particles into tumor tissue can for example be compromised
by size and capture in the extracellular matrix [105]. 3D tumor models
could therefore help in making a better prediction on the eﬀectiveness of a
certain therapy as an intermediate step between simple in vitro and in vivo
experiments.
Alternatively, primary solid gynecologic tumors and malignant as-
cites from ovarian cancer patients can be used instead of cell lines [82].
These model systems can provide a more realistic representation of the
clinical setting. However, the use of primary tumor material results in
heterogeneity between samples and even within one sample. Larger
numbers of samples are therefore needed to obtain statistically reliable
results.
In vivo, drug delivery systems were validated in murine models.
Most studies used immunodeﬁcient athymic nude BALB/c mice and two
studies used severe combined immunodeﬁcient (SCID) mice in order to
establish a xenograft model [27,70]. Goldberg et al. used athymic nude
BALB/c mice, but also immunocompetent FVB/NJ mice in which tumor
growth was possible by utilizing a murine ovarian cancer cell line [77].
The authors did not report any diﬀerences in outcome between the
immunodeﬁcient and immunocompetent mice. A similar strategy was
used by Huang et al. as they established a tumor model by injecting
C57BL/6J (black six) mice with murine ovarian surface epithelium
derived ID8-Fluc cells [83]. The last group to use immunocompetent
mice studied macrophages in ICR mice without establishing a tumor
altogether [75]. Immunodeﬁcient mice have to be used to develop xe-
nografts from human origin. Studying the interactions of novel drugs
and the immune system is unfortunately not possible in these models.
Knowledge of these interactions is nevertheless very important since
other therapies such as chemotherapeutics are notorious for bone
marrow depression. Furthermore, the majority of these tumors con-
sisted of the questionable SK-OV-3 cells. Unfortunately, it has not been
validated as to which degree immunodeﬁcient animals reproduce the
essential characteristics of EOC.
A large source of variation between in vivo models is the tumor lo-
cation, which is either subcutaneous or intraperitoneal. A subcutaneous
tumor has the advantage to be easily accessible and easy to monitor
over time without sacriﬁcing the animal. In contrast, an intraperitoneal
model is more realistic though tumor morphology and tumor micro-
environment may still be diﬀerent from the human situation. For ex-
ample, only OVCAR-8 cells were able to form ascites after IP inocula-
tion in a study that analyzed the in vivo growth of 11 diﬀerent ovarian
cancer cell lines [106]. Unfortunately, the only study utilizing OVCAR-
8 in this review used a subcutaneous tumor model [27]. Cells such as
KURAMOCHI and OVSAHO cells are genetically closer to primary
tumor tissue than SK-OV-3 cells [104]. However, these cells only grow
in SCID mice and show a disseminated growth pattern as compared to
SK-OV-3 cells which show oligometastatic growth [107]. Lastly, ex-
perimental bias can occur as, for example, animal randomization was
not performed in most studies. If the guideline on the assessment of risk
of bias in animal studies was followed, most experiments could be
improved in order to make their results more valid [108]. A more
systematic comparison of injection routes in murine models should also
be instructive. An exception with very little predictive relevance is in-
tratumoral injection of subcutaneous tumors as this neglects the highly
disseminated nature of late stage ovarian cancer and is therefore not
clinically relevant.
Astonishingly, in the ﬁeld of siRNA delivery there has been little
consideration as to which degree IP therapy requires characteristics
that diﬀer from those of other application routes. For example, to which
extend does particle size aﬀect extravasation into systemic circulation?
To which degree is surface shielding required if there is no contact with
the reticuloendothelial system? Are there diﬀerences in the require-
ments for degradation versus excretion? To which degree is the presence
of targeted receptors such as the folate receptor on other cell types a
concern, if entry into systemic circulation is highly delayed and/or
reduced?
In conclusion, numerous delivery techniques, targets, and siRNAs
have been studied in the context of EOC. All methods seem successful
due to a positive publication bias and drug delivery systems have a
tendency towards increasing complexity since many groups strive to
continuously improve the characteristics of a speciﬁc delivery for-
mulation in their own line of research. What is urgently needed is a
critical cross validation of delivery approaches in a clinically relevant
context. For example, the polymer-based formulations with the most
beneﬁcial activity to toxicity ratio need to be compared to LNPs for
systemic and IP application. A further criterion should be the necessity
for targeting and shielding. Activity in combination with simplicity
should be the ultimate design rationale.
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